Additionally, codeletion of 1p/19q and IDH mutation with either mutant TERT promoter or ATRX has been reported to be closely associated with better prognosis of glioma patients (Eckel-Passow et al., 2015; Louis et al., 2021), and MGMT promoter methylation has been shown capable of predicting better response to temozolomide, a first-line chemotherapy for glioblastomas (Hegi et al., 2005). This evidence concerns the gene ATRX and glioma.